register

News & Trends - Pharmaceuticals

Takeda’s $200 million loss as Novartis withdraws marketing application

Health Industry Hub | July 1, 2020 |

Takeda announced the anticipated financial loss from Novartis’ withdrawal of the marketing application for Xiidra.

Xiidra (lifitegrast ophthalmic solution 5%) is the first and only prescription treatment approved by the U.S. Food and Drug Administration for both signs and symptoms of moderate- severe dry eye disease, with a mechanism of action that targets inflammation. It was one of the products obtained through the acquisition of Shire by Takeda in January 2019.

In July 2019, Takeda completed the sale of Xiidra to Novartis for a sales price of $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone receipts, including certain sales-based milestones.

As a result of Novartis’ withdrawal of the marketing application for Xiidra in Europe, Takeda expects that the probability of receiving certain sales-based milestones may be reduced, although the total potential milestone receipts of up to $1.9 billion remain unchanged. As a result of the remeasurement, Takeda anticipates that it will recognise a loss of approximately $200 million for the three-month period ending June 30, 2020.

Takeda will continue its $10 billion of divestitures of its non-core business to pay off its merger debts. 

Xiidra was registered in Australia by Shire and sponsorship transferred to Novartis in September 2019.


News & Trends - MedTech & Diagnostics

Government's claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies

Health Industry Hub | February 7, 2025 |

The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]

More


News & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election

Healthcare sector’s political donations: What to expect ahead of the federal election

Health Industry Hub | February 7, 2025 |

Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]

More


News & Trends - Pharmaceuticals

'Underinvestment in gynae cancer has left critical gaps,' says ANZGOG Chair

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair

Health Industry Hub | February 7, 2025 |

Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]

More


News & Trends - MedTech & Diagnostics

Labor's one-off funding a band aid for public hospitals while private sector left in limbo

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo

Health Industry Hub | February 6, 2025 |

The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]

More


This content is copyright protected. Please subscribe to gain access.